Loading...
Market
Story
NIAID-Funded Study Analyzes 47 Strains of Lyme Disease Bacteria to Advance Treatment
Aug 16, 2024, 01:00 PM
A new genetic analysis of Lyme disease-causing bacteria has been conducted by an international team of scientists, revealing the genetic makeup of 47 strains of known and potential bacteria responsible for the disease. This research, funded by the National Institute of Allergy and Infectious Diseases (NIAID), aims to improve the diagnosis and treatment of Lyme disease. The study provides insights into the history and future of Borrelia bacteria, which cause Lyme disease, and could significantly propel advancements in the field. The findings highlight the widespread nature of the tick-borne infection and offer potential pathways for developing new treatments.
View original story
Similar markets
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Identification of new biomarkers • 25%
Development of new treatment protocols • 25%
Discovery of new disease pathways • 25%
No significant findings • 25%
Pfizer • 25%
Merck • 25%
GlaxoSmithKline • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
